Current Report Filing (8-k)
March 08 2016 - 4:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 7, 2016
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889 |
|
94-3248524 |
(Commission File No.) |
|
(IRS Employer Identification No.) |
1180 Veterans Boulevard
South San Francisco, CA 94080
(Address of principal executive offices)
94080
(Zip Code)
Registrants telephone number, including area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)
On March 8, 2016, Rigel Pharmaceuticals, Inc. (the Company) announced the appointment of Anne-Marie Duliege, M.D., M.S. to the role of Chief Medical Officer of the Company. Dr. Duliege succeeds Elliot Grossbard, M.D., who has served with Company in numerous positions over the last 14 years, most recently as Chief Medical Officer. In connection with Dr. Dulieges appointment as Chief Medical Officer, on March 7, 2016, Dr. Grossbard retired from that position, and will remain with the Company, advising on the new drug application filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura.
A copy of the Companys press release, titled Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer, is furnished as Exhibit 99.1 hereto and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1 Press release, dated March 8, 2016, titled Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 8, 2016 |
RIGEL PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Dolly A. Vance |
|
Dolly A. Vance |
|
Executive Vice President, General Counsel and Corporate Secretary |
|
|
|
3
EXHIBIT INDEX
Exhibit Number |
|
Description |
99.1 |
|
Press release, dated March 8, 2016, titled Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer. |
4
Exhibit 99.1
Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
Elliott Grossbard, M.D. Retires; Continues Advising on Fostamatinib in the ITP Program
SOUTH SAN FRANCISCO, Calif., March 8, 2016 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Anne-Marie Duliege, M.D., M.S. to the role of chief medical officer, replacing Elliott Grossbard, M.D., who is retiring from that position after 14 years with the company. Dr. Grossbard will remain with the company, advising on the new drug application (NDA) filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura (ITP).
We feel very fortunate to have Anne-Marie join Rigels management team. Her experience overseeing hematology product approvals will be put to immediate use at this crucial stage in our fostamatinib program, and she will play a significant role in the advancement of our entire product pipeline, said Raul Rodriguez, president and chief executive officer of Rigel. We are very grateful for the many contributions that Elliott has made to Rigel and our product development programs, and we continue to rely on him as we file and manage the NDA for fostamatinib in ITP, he added.
Dr. Duliege has extensive experience in the biopharmaceutical industry, including having held leadership positions in clinical research and development at Genentech, Inc. and Chiron Corporation, and most recently serving as chief of strategic development and head of immuno-oncology at ChemoCentryx, Inc. From 2004 to 2013, she was a member of the executive team at Affymax, Inc. where she was responsible for providing critical pipeline development results in support of that companys initial public offering and follow-on public offerings, as well as business development projects, including a major partnership with Takeda, Inc. She ultimately held the position of chief medical officer and head of research and clinical development at Affymax, having grown the clinical development organization and successfully managed the development of its first marketed product through international clinical studies, resulting in NDA approval by the FDA. In that role, she was responsible for working closely with the FDA on product label and post-marketing requirements, as well as the strategy and implementation of significant post-launch epidemiological studies.
Dr. Duliege received her Doctorate of Medicine and her certification in Pediatrics from Paris Medical School, where she also received an M.S. in Biostatistics, and holds an M.S. in Epidemiology from the Harvard School of Public Health. She is an Adjunct Clinical Assistant Professor at Stanfords School of Medicine and the Lucile Packard Childrens Hospital. She also serves on the board of CIRM, the California Institute for Regenerative Medicine.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigels pioneering research focuses on signaling pathways that are critical to disease mechanisms. The companys current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.
This press release contains forward-looking statements, including, without limitation, statements related to Rigels clinical development plans, including the timing, design and nature of planned clinical trials and the timing and nature of results of those trials. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as planned, will, may, expect, and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Rigels current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the availability of resources to develop Rigels product candidates, Rigels need for additional capital in the future to sufficiently fund Rigels operations and research, the uncertain timing of completion of and the success of clinical trials, market competition, risks associated with and Rigels dependence on Rigels corporate partnerships, as well as other risks detailed from time to time in Rigels reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.
# # #
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
Media Contact: Susan C. Rogers, Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Sep 2023 to Sep 2024